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A subpopulation of cancer cells with stem cell properties is responsible for tumor formation, main-
tenance, and malignant progression; however, the molecular mechanisms underlying the mainte-
nance of cancer stem-like cell properties have remained unclear. Here, we show that the Rho
family GTPase Rac1 is involved in the glioma stem-like cell (GSLC) maintenance and tumorigenicity
in human glioma. The Rac1-Pak signaling was markedly activated in GSLCs. Knockdown of Rac1
caused reduction of expression of GSLC markers, self-renewal-related proteins and neurosphere for-
mation. Moreover, down-regulation of Rac1 suppressed the migration, invasion, and malignant
transformation in GSLCs. Furthermore, inhibition of Rac1 enhanced radiation sensitivity of GSLCs.
These results indicate that the small GTPase Rac1 is involved in the maintenance of stemness and
malignancies in GSLCs.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction survival, loss of epithelial cell properties, and abnormal cellAn increasing body of evidence suggests that a subpopulation of
cancer cells with stem-like cell properties is responsible for tumor
formation [1,2] and maintenance and malignant progression [3–5].
These rare tumor cells, termed cancer stem-like cells or cancer-ini-
tiating cells, are characterized by their strong tumorigenic proper-
ties and ability to self-renewal [6,7]. Therefore, development of
novel therapeutic strategies that speciﬁcally target cancer stem-
like cells may more effectively eradicate malignant tumors than
conventional treatments, while reducing the risk of relapse and
metastasis. It is critical to understand how the properties of cancer
stem-like cells make them particularly difﬁcult to eradicate.
However, the molecular features of cancer stem-like cells that
orchestrate the enrichment and maintenance of stemness and
tumorigenic properties remain to be elucidated.
Members of the Rho GTPase family Rac, CDC42, and Rho have
been shown to be implicated in uncontrolled proliferation,chemical Societies. Published by E
GF, basic ﬁbroblast growth
irpin RNA
hemistry, Research Institute
791, Republic of Korea (M.-J.migration [8–11], and for that reason, Rho GTPases have been
suggested to control the tumor formation and malignant progres-
sion in human cancers [12–14]. Emerging evidence indicates that
Rac1-dependent signal transduction is essential for malignant cell
transformation [15,16]. Moreover, total expression and activity
levels of Rac1 are much higher in several types of human cancers
than their normal tissues [13,17,18], and a high level of Rac1 plays
a fundamental role in cell survival and maintenance of malignant
phenotype of high-grade glioma cells [15,19,20]. In these studies,
a high expression level of Rac1 is correlated with rapid
proliferation and survival of glioma cells, and inhibition of Rac1
greatly reduces glioma proliferation, and induces apoptotic cell
death in patient derived glioma cells [21]. These observations
have led to the concept that inappropriate expression and activa-
tion of Rac1 is involved in the development and promotion of
cancer; however, the molecular mechanisms by which small
GTPase Rac1 might contribute to these processes have remained
obscure.
The aim of this study was to ﬁnd out the role of the Rho GTPase
family Rac1 in the maintenance of malignant phenotypes in human
glioma cells. Our results show that activation of Rac1 is critically
involved in the enrichment of the glioma stem-like cell population
and the maintenance of malignancies. The ﬁndings of this studylsevier B.V. All rights reserved.
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against malignant brain cancer.
2. Materials and methods
2.1. Cell, chemical reagents, and antibodies
U87MG and U373MG (glioma cancer cells) were obtained from
the Korean Cell Line Bank (KCLB) and cultured in Dulbecco’s Modi-
ﬁed Eagle Medium (DMEM) containing 10% fetal bovine serum
(FBS), 100 U/ml penicillin and 100 mg/ml streptomycin in a humid-
iﬁed incubator at 37 C with 5% CO2 atmosphere. For the process of
isolation and identiﬁcation of glioma stem cells (U87 spheres and
U373 spheres), U87MG and U373MGwere collected and inoculated
into a serum-free medium which contained DMEM/F12 with high
glucose medium, 20 ng/ml of epidermal growth factor (EGF), basic
ﬁbroblast growth factor (bFGF) and B27 (1X). The cells were placed
in incubator on conditions of 37 C, 5% CO2 atmosphere. In every 3–
4 days the medium was renewed [22,23].
Polyclonal antibody CD133 and Snail were obtained from
Abcam, and Rac/cdc42 assay reagent (PAK1 PBD, agarose), poly-
clonal antibodies to anti-nestin, anti-Musashi1 were purchased
from Millipore. The monoclonal antibody Rac1, CDC42 and Annex-
in V-FITC were obtained from BD Transduction Laboratories™.
Polyclonal antibody Slug and Zeb1 were obtained from Santa Cruz.
The polyclonal antibody Vimentin was obtained from Thermo Sci-
ence. 4,6-Diamidino-2-phenylindole (DAPI), EGF and monoclonal
anti-b-actin were obtained from Sigma. bFGF was purchased from
R&D Systems. Anti-mouse Alexa Fluor 488, anti-rabbit Alexa Flour
488 and B27 were purchased from Invitrogen. CD133 (directly con-
jugated with phycoerythrin, clone 293C3) and mIgG2b-PE were
purchased from Miltenyi Biotech Ltd.
2.2. Spheres culture
U87MG and U373MG cells were resuspended in DMEM-F12
(Invitrogen) containing 20 ng/ml of EGF, bFGF and B27 (1X) as a
stem cell–permissive medium. Spheres were collected after 5–
7 days, and protein was extracted for additional experiments or
dissociated with Accutase (Innovative Cell Technologies Inc.) for
expansion [24,25].
2.3. Sphere colony counting
Sphere-forming glioma cells were ﬁrst distributed into 96-well
plates at a density of 1–2 cells/well. After 12 h, individual wells
were visually checked for the presence of a single cell. The clones
were grown and tested for the neurospheres formation. Neuro-
spheres with a diameter >20 lm were counted using an inverted
microscope at days 1, 4, 7 and 10 [26].
2.4. Flow cytometric analyses
Cells were dissociated and resuspended in PBS containing 0.5%
bovine serum albumin. For magnetic labeling, CD133 Micro Beads
were used (Miltenyi Biotech). Positive magnetic cell separation
(MACS) was done using 25MS MACS columns in series. Cells were
stained with CD133/2-PE (Miltenyi Biotech) or isotype control
antibody (mIgG2b-PE, Miltenyi Biotech) and analyzed on a BD FAC-
SCalibur ﬂow cytometer.
2.5. Small interfering RNA (siRNA) transfection
siRNA targeting of Rac1 was performed using 21 base pairs
(including a 2-deoxynucleotide overhang). siRNA target of Rac1was purchased from Samchully Pharmaceutical Co. Ltd. (Seoul,
Korea). A control siRNA speciﬁc for green ﬂuorescent protein
(50-CCACTACCTGAGCACCCAG-30) was used as the negative control.
siRNA duplexes (40 nM) were introduced into cells using a Micro-
porator-mini (Invitrogen) by following the procedure recom-
mended by the manufacturer. After 48 h, the medium was added,
and cells were harvested for additional experiments.
2.6. Lentiviral shRNA experiments
Small hairpin RNA (shRNA) constructs against human Rac1 was
purchased from OriGene Technologies Inc. (Rockville, MD) (shRNA
Rac1; Clone ID TRCN0000004870, non-targeting shRNA; Sigma–
Aldrich SHC002). 293T cells were seeded (3  106 cells/ml) in
60-mm dish. Lentiviral particles were generated using a three-plas-
mid system, as described previously [27,28]. To standardize lentiv-
iral transduction assays, viral titers were measured in a benchmark
cell line, A549. For growth assays, titers corresponding tomultiplic-
ities of infection (MOIs) of 5 and 1 in A549 cells were employed. For
Rac1 knockdown, cells were plated on day zero at 1  105 cells/ml
in 60-mmdishes. Twenty-four hours after infection, cells were trea-
ted with 1 lg/ml puromycin for 1 days to eliminate uninfected
cells. Media was replaced and after 2 more days, cells were har-
vested for Western blot or for additional experiments.
2.7. Rac1 activation assay
Cells were lysed lysis buffer [40 mM Tris–HCl (pH 8.0), 120 mM
NaCl, 0.1% Nonidet-P40] supplemented with protease inhibitors.
For Rac/cdc42 assay, Cellular debris was removed by centrifugation
at 13 200 rpm for 15 min at 4 C. Protein concentrations were
determined using Bio-Rad protein assay reagents, and total cell ly-
sate (300 lg protein in 0.3 ml) was immunoprecipitated with
10 lg PAK-1 PBD agarose bead (for RAC and CDC42) at 4 C for
3 h. After washing three times with lysis buffer, the pull-out
GTP-bound RAC/CDC42 protein was eluted by boiling in SDS-sam-
ple buffer and evaluated by Western blot analysis.
2.8. Western blot analysis
Cell lysates were prepared by extracting proteins with lysis buf-
fer [40 mM Tris–HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet-P40]
supplemented with protease inhibitors. Proteins were separated
by sodium dodecyl sulfate–polyacrylamide (SDS) gel electrophore-
sis and transferred to a nitrocellulose membrane (Amersham
Biosciences, Arlington Heights, IL). The membrane was blocked
with 5% non-fat dry milk in Tris-buffered saline and incubated with
primary antibodies for overnight at 4 C. Blots were developed
with a peroxidase-conjugated secondary antibody and proteins
visualized by enhanced chemiluminescence (ECL, Amersham)
procedures, using the manufacturer’s protocol.
2.9. Invasion and motility assays
Cells (2  104 cells/well) were suspended in 0.2 ml of serum-
free DMEM or serum-free DMEM-F12 supplemented with B27,
FGF and hEGF for invasion and motility assays. For invasion assay,
the cells were loaded in the upper well of the Transwell chamber
(8-mm pore size; Corning, Corning, NY) that was precoated with
10 mg/ml growth factor reduced (BD Matrigel™ matrix – BD Bio-
sciences) on an upper side of the chamber with the lower well
ﬁlled with 0.8 ml of serum-free DMEM or serum-free DMEM-
F12 supplemented with B27, FGF and hEGF. After incubation for
48 h at 37 C, non-invaded cells on the upper surface of the ﬁlter
were removed with a cotton swab, and migrated cells on the low-
er surface of the ﬁlter were ﬁxed and stained with a Diff-Quick kit
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Invasiveness was determined by counting cells in ﬁve microscopic
ﬁelds per well, and the extent of invasion was expressed as an
average number of cells per microscopic ﬁeld. Cells were imaged
with by phase-contrast microscopy (Leica Microsystems, Ban-
nockburn, IL).
For motility studies, we used invasion chambers with control
inserts that contained the same type of membrane but without
the Matrigel coating (one chamber per well of a 24-well plate).
2  104 cells in 0.2 ml of serum-free DMEM or serum-free
DMEM-F12 supplemented with B27, FGF and hEGF were added
to the apical side of each insert, and 0.8 ml of serum-free DMEM
was added to the basal side of each insert. The inserts were
processed as described above for the invasion assay.
2.10. Soft agar colony formation assay
To examine anchorage-independent growth, a cell suspension
(2  104 cells) were suspended in 0.4% agarose with serum-free
DMEM-F12 supplemented with B27, FGF and hEGF and seeded in
triplicate on 60-mm dishes pre-coated with 0.8% agar in complete
growth medium and incubated at 37 C, 5% CO2. After 12–30 days,
colonies were photographed and counted in four randomly chosen
ﬁelds and expressed as means of triplicates, representative of two
independent experiments.
2.11. Tumor xenografts on nude mice
After transfection with shRNA, U373 sphere forming glioma
cells (4  104) were subcutaneously inoculated to the right ﬂank
of athymic Balb/c female nude mice (5 weeks of age). Tumor size
was measured with a caliper (calculated volume = shortest diame-
ter2  longest diameter/2) at 5 day intervals. This study was re-
viewed and approved by the Institutional Animal Care and Use
Committee (IACUC) of Korea Institute of Radiological and Medical
Sciences (KIRAMS).
2.12. Quantiﬁcation of cell death
FACS analysis using propidium iodide (PI) staining detects cell
death by means of the dye entering the cells along with changes
in the target cell membrane and DNA damage. For the cell-death
assessment, cells were harvested by trypsinization, washed in
PBS, and then incubated in propidium iodide (50 ng/ml) for
5 min at room temperature. Then, cells (10 000 per sample) were
analyzed on a BD FACSCalibur ﬂow cytometer, using Cell Quest
software (BD Biosciences).
2.13. Immunoﬂuorescent staining
Immunocytochemistry of tumor spheres was performed as de-
scribed [5]. Antibodies used were as follows: human anti-CD133
(1:200), -nestin (1:200) and -musashi1 (1:200) for the detection
of neural stem. Stainings were visualized using anti-mouse Alexa
Fluor 488 and anti-rabbit Alexa Flour 488 (Molecular Probes). Nu-
clei were counterstained using 4,6-diamidino-2-phenylindole
(DAPI; Sigma). Stained cells were visualized with a ﬂuorescence-
microscope (Olympus IX71).
2.14. Statistical analysis
All the data in the study were performed in triplicate. The
results are described as mean ± S.D. Statistical analysis was
performed by one-way analysis of variance (ANOVA) and compar-
isons among groups were performed by independent sample t-test.
Differences were considered signiﬁcant at values of ⁄P < 0.001.3. Results and discussion
3.1. Rac1 is involved in the maintenance of glioma stem-like cells
Rho family small GTPase Rac1 has been implicated in the
tumor formation and malignant progression in human glioma
[1–5]. To examine whether Rac1 is involved in the maintenance
of glioma stem-like cells, we ﬁrst examined the activation status
of Rac1 in glioma stem-like cells using Rac1-PAK binding assay.
As shown in Fig. 1A, binding activity of Rac1 to PAK was markedly
increased in U87 and U373 glioma cells grown under sphere-
forming conditions compared to matched glioma cells grown as
a monolayer. There was no change in Rac1 at the total protein
level. To further determine whether the activation of Rac1 is
required for the maintenance of the glioma stem-like cell
population.
To further study the involvement of Rac1 in the maintenance
of the glioma stem-like cell population, we down-regulated
Rac1 in sphere forming U87 and U373 glioma cells by treatment
with siRNA. Treatment with siRNA or shRNA targeted to Rac1
speciﬁcally down-regulated Rac1, while the expression levels of
b-actin and other GTpase, CDC42 were not altered (Fig. S1A).
Importantly, treatment with siRNA targeting of Rac1 resulted in
the increase of binding activity of Rac1 to PAK and a marked de-
crease in the number of spheres (Fig. 1B). Moreover, the CD133+
cell population was clearly suppressed by siRNA-mediated knock-
down of Rac1 (Fig. 1C). Treatment with siRNA targeted to Rac1
also attenuated expression of glioma stem-like cell marker pro-
teins, CD133, Nestin and Musashi-1 (Fig. 1D). In addition, a ﬂuo-
rescence microscopic analysis of cells immunostained with
antibodies speciﬁc for the marker proteins clearly revealed that
siRNA targeting of Rac1 effectively suppressed expression level
of CD133, Nestin, and Musashi-1 (Fig. 1E). These results speciﬁ-
cally implicate Rac1 in the maintenance of glioma stem-like cell
population.3.2. Activation of Rac1 is critical for the proliferation and self-renewal
in glioma stem-like cells
Enhanced self-renewal ability is one of the key characteristics of
cancer stem-like cells. To determine whether Rac1 is critical for the
proliferation and self-renewal in glioma stem-like cells, we
inhibited Rac1 expression with siRNA and examined changes in
self-renewal potential using an in vitro self-renewal assay, and also
examined changes in the expression levels of the known self-re-
newal-related proteins Sox2, Notch1/2, and b-catenin. As shown
in Fig. 2A, treatment with siRNA targeted to Rac1 clearly inhibited
sphere-forming ability of glioma stem-like cells at single cell levels
(self-renewal potential). In contrast, down-regulation of Rac1 in
monolayer-cultured glioma cells did not suppress cell growth
(Fig. S1B), suggesting that Rac1 is required only for the prolifera-
tion of glioma stem-like cells, but not monolayer-cultured cells.
Consistent with these results, the expression of self-renewal-re-
lated proteins Sox2, Notch2 and b-catenin was markedly higher
in sphere forming glioma cells, compared to monolayer-cultured
glioma cells (Fig. 2B), again conﬁrming that glioma stem-like cells
are highly enriched in sphere forming glioma cells more than
monolayer-cultured cells. Importantly, treatment with siRNA
targeted to Rac1 led to a decrease of Sox2, Notch2, and b-catenin
at the protein level in sphere-forming glioma stem-like cells, but
did not affect the level of Notch1 (Fig. 2B). Since treatment with
siRNA speciﬁcally targeted to Rac1 (Fig. S1A) and siRNA-mediated
down-regulation of Rac1 was sustained at least for 10 days
(Fig. S1C), Rac1 would be directly involved in down-regulation of
self-renewal-related proteins, thereby suppressing sphere
Fig. 1. (A) U87 and U373 monolayers or spheres lysates were immunoprecipitated with 10 lg PAK-1 PBD agarose bead. Total proteins were subjected to immunoblot analysis
with anti-Rac1 and b-actin antibodies. b-Actin was used as the loading control. (B) U87 and U373 spheres were transfected with si-RNA of Rac1 or control. (Left) After 48 h,
total cell lysates was immunoprecipitated with 10 lg PAK-1 PBD agarose bead. And proteins were subjected to immunoblot analysis with anti-Rac1 and b-actin antibodies. b-
Actin was used as the loading control. (Right) Graph shows the number of spheres per visual ﬁeld of microscopy. Error bars represent mean ± S.D. of ﬁve different ﬁelds. An
asterisk () indicates P < 0.001 with one-way ANOVA comparison of the control groups to the corresponding Rac1 inhibition groups. (C) U87 and U373 spheres were
transfected with either si-RNA of Rac1 or control. After 48 h, cells were analyzed for the expression of glioma-stem cell marker CD133 by ﬂow cytometry. Error bars represent
mean ± S.D. of triplicate samples. An asterisk () indicates P < 0.001 with one-way ANOVA comparison of the control groups to the corresponding Rac1 inhibition groups. (D)
After 48 h, total cell lysates were subjected to immunoblot analysis with anti-CD133, -Nestin, or -Musashi1 antibodies. b-Actin was used as the loading control. (E) U87 and
U373 spheres were transfected with either si-RNA of Rac1 or control. After 48 h, cells were stained with FITC-conjugated with anti-CD133, -Nestin, or -Musashi1 antibodies
and imaged by ﬂuorescence microscopy (Olympus IX71). Photomicrographs were taken at magniﬁcation 400.
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Fig. 2. (A) U87 and U373 sphere were transfected with either control-siRNA or si-Rac1. Cells were then distributed into 96-well plates at a density of 1 cell/well. The ability of
a single clone to form new spheres was tested by microscopy after 10 days. (Left) Images represent changes in spheres size in the presence of control-siRNA or si-Rac1
(magniﬁcation 200). (Right) Number of clones forming spheres with a diameter >20 lm was counted using inverted in the presence of control-siRNA or si-Rac1. Error bars
represent mean ± S.D. of triplicate samples. An asterisk () indicate respectively P < 0.001 with one-way ANOVA comparison of the control groups to the corresponding Rac1
inhibition groups. (B) U87 and U373 sphere were transfected with either control-siRNA or si-Rac1. After 48 h, total cell lysates were subjected to immunoblot analysis with
anti-Notch1/2, -Sox2, -b-catenin, and Rac1 antibodies. b-Actin was used as the loading control.
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down-regulation of Notch, Sox2 and b-catenin led to a decrease
of sphere formation [33–35].
To conﬁrm the role of Rac1 in the stemness of glioma stem-like
cell population, we also treated patient-derived glioma stem-like
cells (X01GB) with siRNA targeting of Rac1, and examined changes
in the CD133+ cell population, sphere formation, and self-renewal
potential. As shown in Fig. S2A, siRNA-mediated Rac1 knockdown
reduced the CD133+ cell population and decreased the number of
spheres. The self-renewal potential in patient-derived glioma
stem-like cells was also inhibited by down-regulation of Rac1
(Fig. S2B). Taken together, these results suggest that Rac1 plays a
critical role in the maintenance of stemness in glioma stem-like
cells.
3.3. Rac1 is involved in the maintenance of the malignant properties of
glioma stem-like cells
We next examined whether Rac1 is required for maintenance of
the malignant properties of sphere forming glioma cells. To this
end, we treated sphere-forming glioma cells with shRNA and
examined anchorage-independent colony formation in soft agar.
Contrary to normal cells that do not proliferate without anchorage,
tumorigenic cancer cells can grow in a condition without anchor-
age such as semisolid medium. Thus, colony forming assay in soft
agar is widely adapted to measure tumorigenic capacity in vitro, as
a good predictor of tumor forming ability in vivo. As shown in
Fig. 3A, shRNA-mediated knockdown of Rac1 effectively attenuatedcolony formation of sphere forming glioma cells in soft agar. To
further test the involvement of Rac1 in the maintenance of
malignant potential in sphere forming cells, we inhibited Rac1
expression with siRNA and analyzed changes in cellular invasion
and migration. Notably, invasive behavior and cell migration
potential of glioma stem-like cells were markedly suppressed by
down-regulation of Rac1 (Fig. 3B and C). These results indicate that
Rac1 is involved in the maintenance of malignant potential in
cancer stem-like cell population.
A mesenchymal phenotype is the hallmark of tumor aggressive-
ness in human malignant glioma. To further test whether Rac1 is
critical for maintenance of mesenchymal phenotype in glioma
stem-like cells, we knocked down Rac1 with siRNA and analyzed
changes in protein expression levels of mesenchymal cell markers
N-cadherin and Vimentin, and the transcription repressors Zeb1,
Snail, and Slug. As expected, expression levels of mesenchymal cell
markers and the transcription repressors were much higher in
sphere forming glioma stem-like cells than matched glioma cells
grown as a monolayer (data not shown). Importantly, knockdown
of Rac1 with siRNA clearly suppressed N-cadherin and Vimentin in
glioma stem-like cells (Fig. 3D). Moreover, treatment with siRNA
targeted to Rac1 effectively inhibited expression of Zeb1 and Slug
proteins, though the protein level of Snail was not altered. These
results indicate that Rac1 plays a critical role for the maintenance
of mesenchymal phenotype in glioma stem-like cells.
Since down-regulation of Rac1 attenuated colony formation in
soft agar and suppressed cell migration and invasion in vitro, we
next examined whether Rac1 is required for tumor formation in
Fig. 3. (A) U87 and U373 sphere were infected with either scramble-shRNA or sh-Rac1 virus, and after 24 h with 1 lg/ml puromycin, infected cells (2  104 cells/ml) were
seeded in soft agar plate. The colonies were calculated relative to 1000 cells during 4 weeks of plating. (Left) The colony was determined by counting cells in randomly
selected four microscopic ﬁelds per plate. Photomicrographs were taken at magniﬁcation 200. (Right) Graph shows the number of spheres per visual ﬁeld of microscopy in
the presence of scramble-shRNA or sh-Rac1 virus. Error bars represent mean ± S.D. of four different ﬁelds. An asterisk () indicates P < 0.001 with one-way ANOVA comparison
of the control groups to the corresponding Rac1 inhibition groups. (B) U87 and U373 monolayers or spheres were transfected with either control-siRNA or si-Rac1, and then
the cells (2  104 cells/well) were seeded in each Matrigel chamber and cultured in serum-free DMEM-F12 supplemented with B27, FGF and hEGF for 48 h. (Left) Invaded cells
were ﬁxed and stained with a Diff-Quick kit and photographed (magniﬁcation 100). (Right) Invasiveness was determined by counting cells in randomly selected ﬁve
microscopic ﬁelds per well. Bars represent mean ± S.D. of triplicate samples. An asterisk () indicates P < 0.001 with one-way ANOVA comparison of the control groups to the
corresponding Rac1 inhibition groups. (C) U87 and U373 monolayers or spheres were transfected with either control-siRNA or si-Rac1, and then the cells (2  104 cells/well)
were seeded in each chamber (without the Matrigel) and cultured in serum-free DMEM-F12 supplemented with B27, FGF and hEGF for 48 h. (Left) Migrated cells were ﬁxed
and stained with a Diff-Quick kit and photographed (magniﬁcation 100). (Right) Cell migration was determined by counting cells in randomly selected ﬁve microscopic
ﬁelds per well. Error bars represent mean ± S.D. of triplicate samples. An asterisk () indicates P < 0.001 with one-way ANOVA comparison of the control groups to the
corresponding Rac1 inhibition groups. (D) U87 and U373 spheres were transfected with either control-siRNA or si-Rac1, and after 48 h, total cell lysates were subjected to
immunoblot analysis with anti-N-cadherin, -Vimentin, -Zeb1, -Snail, or -Slug antibodies. b-Actin was used as the loading control.
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Fig. 4. U373 sphere forming glioma cells were transfected with either control
scrambled shRNA or sh-Rac1. Transfected cells were then subcutaneously inocu-
lated to the right ﬂank of athymic Balb/c female nude mice (5 weeks of age, n = 4
per group). Tumor size was measured with a caliper (calculated volume = shortest
diameter2  longest diameter/2) at 5 day intervals. Representative photos shows
differential volume of tumor at 35 days. Error bars represent mean ± S.D. ⁄P < 0.001.
Fig. 5. U87 and U373 spheres were transfected with either control-siRNA or si-
Rac1. Cells were then treated with ionizing radiation (10 Gy) and etoposide
(10 lM). After 48 h, cell death was assessed by ﬂow cytometry as described in
Section 2. Error bars represent mean ± S.D. of triplicate samples.
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targeted to Rac1 and then transplanted to athymic Balb/c female
nude mice subcutaneously. Notably, tumor formation was dramat-
ically attenuated in mice transplanted with U373 sphere-derived
glioma cells treated with shRNA Rac1, compared to scrambled
shRNA (Fig. 4). Taken together, these results have implications that
Rac1 is a critical regulator in vitro and in vivo for maintenance of
the malignant properties in glioma stem-like cells.
3.4. Rac1 is important for the maintenance of resistance to anticancer
treatments in glioma stem-like cells
Cancer stem-like cells have been implicated in the resistance to
chemotherapy and radiotherapy [36,37]. As expected, sphere-
forming glioma cells showed greater resistance to both ionizing
radiation and anticancer drug, etoposide than monolayer cells
(data not shown), conﬁrming that cancer stem-like cells are en-
riched in sphere-cultured glioma cells. To examine whether activa-
tion of Rac1 is involved in the maintenance of resistance to
anticancer treatments in glioma stem-like cells, we inhibited
Rac1 expression with siRNA, and then examined changes in sensi-
tivity of glioma stem-like cells to ionizing radiation and etoposide
in sphere forming glioma stem-like cells. Though single treatment
with ionizing radiation or etoposide or siRNA targeted to Rac1 did
not cause signiﬁcant cell death, pretreatment with siRNA targeted
to Rac1 sensitized sphere forming glioma cells to ionizing radiation
and etoposide, inducing signiﬁcant cell death (Fig. 5). Concurrently
with cell death, we also observed the increase of Annexin V posi-
tive cell population by ionizing radiation or etoposide treatment
only in pretreated sphere forming glioma cells with siRNA targeted
to Rac1 (Fig. S3), indicating that cell death is due to apoptosis. Ta-
ken together, these results suggest that these results indicate that
Rac1 is important for the maintenance of resistance to anticancer
treatments in glioma stem-like cells.
The Rho family small GTPase Rac1 has been implicated in cell
survival and malignant transformation in human cancers including
glioma [15,19,20,29–31]. Similar observations have led to the con-
cept that inappropriate activation of Rac1 is involved in the devel-
opment and promotion of glioma [8,9,12,32]. In this study, we
further found that the Rho family GTPase Rac1 is involved in the
stemness and tumorigenicity in glioma stem-like cells. The Rac1 sig-
naling was markedly activated in sphere forming glioma stem-like
cells. Importantly, inhibition of Rac1 signaling with siRNA reduced
expression of glioma stem-like cell markers and self-renewal-re-
lated proteins as well as sphere formation. Moreover, siRNA-target-
ing of Rac1 effectively suppressed the migration, invasion, and
malignant transformation in sphere forming glioma stem-like cells.Furthermore, siRNA-mediated knockdown of Rac1 effectively en-
hanced radiation sensitivity of glioma stem-like cells. These results
indicate that the small GTPase Rac1 is involved in the maintenance
of stemness and malignancies in the glioma stem-like cells. These
ﬁndings may provide pivotal insights in the context of therapeutic
interventions to target glioma stem-like cell population.
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